It’s little surprise that Tim is ranked in the Legal 500 as a ‘next generation’ pharma and biotech lawyer. With a long-held interest in the field allied to his scientific training, Tim is a firm believer in the transformative power of life sciences and the remarkable impact they can have on people’s lives.
Today Tim's principal focus is on patents and related rights, providing strategic advice and litigation expertise in the English Court and Unified Patents Court principally to innovator biotech and pharma companies. Tim has advised on numerous blockbuster treatments including monoclonal antibody therapies and other biologics, as well as other innovative technologies.
Tim enjoys helping his clients understand, enforce and defend their IP rights and minimise their risks. The approach taken to this work is always collaborative, often working as part of a multi-jurisdictional team he relishes the challenge of forming and deploying creative legal and commercial strategies.
Highly regarded in the wider industry, Tim is a member of the European Patent Lawyers Association (EPLAW) and teaches on Oxford University's Postgraduate Intellectual Property Diploma.
Helping you succeed in tomorrow's world
I enjoy developing and supporting the next generation of lawyers and entrepreneurs. I take pleasure from regularly lecturing, teaching, and working with start-ups and spin-outs to help them understand how to protect their innovations and minimise IP risks.
Advised Amgen on the commerciation of its eculizumab biosimilar (BEKEMV®) in the UK High Court, UPC litigation and pan-European strategy.
Advised Santen on the protection and enforcement of its tafluprost (TAFLOTAN®) patent rights in the UK and across Europe.
Represented Anstar to defend its photoinitiator chemical business in UK High Court patent infringement proceedings.
Advised a large pharmaceutical company in relation to patent rights in direct oral anticoagulants (DOACs).
Represented Block, Inc. (formerly Square, Inc.) defending High Court litigation concerning IP rights in bitcoin.
Advised Eurosemillas SA in relation to the UK aspects of its plant variety rights in a multinational dispute.
Supported Dialight plc in the renegotiation of its patent licence from Signify and the commercialisation of its own patent portfolio.
Advised A-Gas on its IP strategy and enforcement.
Insights
Patents Court upholds validity of second medical use patent for glaucoma treatment
This decision shows the court assessing patentability in a real-world practical context, recognising the uncertainties of R&D that only later...
Would a global vaccine IP waiver stifle future biopharma breakthroughs?
Pressure for an IP rights waiver to fight the pandemic threatens vaccine companies' ability to develop and protect their trade...
Patents Court offers guidance on use of doctrine of equivalents
Decision makes it clear that a patentee must consider their infringement position at an early stage in proceedings
Can gene-editing help solve the energy crisis?
What role can biofuels play in fighting climate change and can CRISPR sequencing technology help it reach its potential?
Battery technology advances are powering the rapid rise of electric vehicles
Patents filed, research and investment are undergoing sustained growth, which is reducing costs in an increasingly mature market
'Crown use' defence in patent infringement claims hinges on authorisation
Appellate-level analysis of rarely used defence limits up-front protection for suppliers of goods and services to government
Judicial changes strengthen English Patents Court
Recent high-profile appointments and developments will bolster the UK's reputation as a forum for litigating complex patent disputes
A new bag of tricks? Obvious if it could have been done before (says the Patents Court)
In order to establish obviousness for the purposes of a patent application, it is enough to show that the idea...
Illuminating insufficiency: the English Patents Court examines "Regeneron ranges"
In applying the insufficiency principles laid down in Regeneron, the High Court highlights some key considerations for patentees looking to...